Tag: Fda approved

According to the Epilepsy Foundation, approximately one-third of people with epilepsy have seizures that are not controlled by existing medications, highlighting the critical need for new anti seizure medications. The past decade has seen the development and approval of novel therapies with unique mechanisms of action, offering new hope for patients with refractory epilepsy.

Dysphagia, or difficulty swallowing, affects millions worldwide and is linked to increased mortality and reduced quality of life. Recent advancements in targeted therapies are reshaping the answer to the question, 'What is the new medication for dysphagia?,' offering specific and effective treatments for certain underlying causes.

According to the FDA, compounded drugs pose a higher risk than approved drugs because they are not tested for safety or efficacy. This is a crucial consideration when asking, **what is the difference between oral and compounded semaglutide?**

In July 2014, the U.S. Food and Drug Administration (FDA) first approved EYLEA (aflibercept) for the treatment of diabetic macular edema (DME). This pivotal approval, based on robust clinical trial data, established EYLEA as a standard of care for a significant complication of diabetic eye disease.

In 2018, the U.S. Food and Drug Administration (FDA) approved stiripentol, marketed under the brand name Diacomit, for treating seizures associated with Dravet syndrome. This milestone confirmed that **is stiripentol available in the USA** for this specific, rare form of epilepsy.

While both belong to a class of drugs called prostaglandin analogs, a common point of confusion is whether **latanoprost and latisse the same thing**. The simple answer is no, and understanding their distinct purposes and formulations is crucial for safe and effective use.

Over the last decade, there has been a significant expansion in the number of FDA-approved drugs for amyloidosis, with distinct treatments now available for different types of the disease. The answer to **What drugs are FDA approved for amyloidosis?** depends on whether a patient has transthyretin (ATTR) or light chain (AL) amyloidosis, as the treatments for each type differ substantially.

An estimated 3% to 5% of non-small cell lung cancer (NSCLC) cases are driven by an abnormal ALK gene. For this specific patient population, targeted therapies provide a range of FDA approved ALK inhibitor options, which have revolutionized treatment outcomes.

According to the Alzheimer's Association, millions of Americans are affected by Alzheimer's, and recent breakthroughs have led to the approval of several new therapies aimed at the underlying pathology. This article explores *what anti-amyloid drugs are FDA approved*, detailing their mechanism of action, key clinical data, and safety profiles for treating early-stage Alzheimer's disease.

LATISSE® (bimatoprost ophthalmic solution) 0.03% is the first and only FDA-approved treatment for eyelash hypotrichosis (inadequate lashes) [1.2.1, 1.5.5]. But is LATISSE safe for eyes, given that its active ingredient was originally for glaucoma treatment? [1.2.4]